Centrosome amplification has been described as a common feature of human cancers and it is known to promote tumorigenesis when induced in animals.
Introduction
The centrosome is the main microtubule (MT) -organizing center of animal cells.
Each centrosome is composed of two centrioles surrounded by pericentriolar material (PCM), which is the site of MT nucleation. The centrosome facilitates the accuracy of chromosome segregation during mitosis and influences cell polarity and migration [1] [2] [3] [4] . Centrosome duplication is normally tightly controlled to ensure that each centrosome duplicates only once per cell cycle 5, 6 . The presence of more than two centrosomes in a cell, centrosome amplification, has long been associated with tumorigenesis, with T. Boveri 7 proposing a link between extra centrosomes, multipolar divisions and consequent aneuploidy. When induced through the manipulation of the centrosome duplication machinery, centrosome amplification, was sufficient to drive tumor formation in vivo in a variety of tissues from different animal models [8] [9] [10] [11] [12] . Interestingly, although the consequences of centrosome amplification have been normally associated with abnormal cell division and the generation of aneuploidy 7, 9, 11, 12 , centrosome amplification can also impact cellular homeostasis in alternative ways. When induced in breast epithelial cells, centrosome amplification resulted in the assembly of invasion-like features, which were RAC1-dependent 13 . More recently, it has been shown that centrosome amplification can drive invasion in a non-cell autonomous manner through increased oxidative stress 14 . Non-cell autonomous detachment of mitotic tumor cells has also been described in organoids containing increased levels of Ninein-like protein, which induces centrosome structural defects [15] [16] [17] . Importantly however, even if many studies have described numerical centrosome defects in cultured cancer cells only a limited number of studies tumors has analyzed centrosome number alterations in situ.
Epithelial ovarian cancers (EOCs) are the most lethal gynecologic malignancies 18, 19 . The high mortality rate is a result of delayed diagnosis and limited therapeutic options despite the use of new drugs, such as the inhibitors of angiogenesis or DNA repair pathways 20, 21 . 75% of EOC patients are diagnosed at advanced disease stages, resulting in a 5-year overall survival rate that has recently been improved from 30 to ~47% 22, 23 . Histological classification includes mainly serous, endometrioid, mucinous and clear cells carcinomas. The most common
EOCs subtype is high-grade serous (HGSOC) which responds at least initially to chemotherapy but presents a worse overall prognosis 24 . Transcriptomic [25] [26] [27] and proteogenomic profiling 28, 29 of HGSOC suggested a whole spectrum of molecular diversity that can be linked to patient survival, without yielding a deep understanding of the mechanism leading to relapse 30 . Moreover, up to 50% of HGSOC exhibit defects in homologous recombination (HR) pathways 26 . HR deficient (HRD) patients with germline or somatic mutations in BRCA1/2 genes are known to be more sensitive to platinum-based chemotherapy and Parp inhibitors than non-BRCAmutated tumors 19, 21, 31 more broadly defined as the HR proficient (HRP) patients.
Since EOCs are characterized by high level of genomic alterations 26, 32 and centrosome numerical defects are associated with aneuploidy, we characterized a large cohort of 100 naive EOCs, comprising 88 HGSOCs, using immunofluorescence and state-of-the-art microscopy. For each tumor, we established the centrosome-nucleus index (CNI) as a proxy to compare centrosome numbers among our cohort. Surprisingly, we found that the frequency of centrosome amplification was less important than what is predicted from the literature. Integration of CNI data with genomic and clinical data revealed a striking association between centrosome amplification and patient outcome. Using patient-derived xenografts (PDXs) and cell line models, we showed that centrosome amplification can positively influence the response to chemotherapy, while it can also inhibit tumor cell dissemination through the mesothelium. Our results demonstrated for the first time that centrosome amplification is not associated with a worse prognosis, but more surprising, they show that decreased centrosome numbers, translate in poorer response to chemotherapy and increased capacity of tumor cell invasion. Overall this study identifies decreased centrosome numbers, but not centrosome amplification, as a condition that favours ovarian cancer progression.
Results

Characterization of centrosome defects in human epithelial ovarian cancer (EOC) tissues
In order to analyze centrosomes in human epithelial ovarian cancers (EOCs), we designed a strategy where 20µm frozen tissue sections were obtained by the pathology department of Institut Curie. These were previously categorized as healthy tissues (corresponding to healthy ovaries from prophylactic oophorectomy or hysterectomy removal) or tumor tissues, which enclosed a mix of serous (90%), endometrioid (3%), mucinous (4%) and clear cell carcinoma (3%) (methods and
Supplementary Table 1) . Importantly, all tumors were naïve, obtained after surgery without previous neo-adjuvant chemotherapy. Tissues were methanol fixed and processed for immunostaining with two different antibodies CDK5RAP2 and pericentrin (PCNT), two PCM components, to unambiguously identify centrosomes through co-localization. Confocal microscopy was used to obtain optical sections from ten random fields in the entire tissue ( Figure 1A ). Analysis of healthy tissues allowed us to identify centrosomes through the co-localization of the two centrosomes markers ( Figure 1B ). We also noticed the presence of structures that only contained one of the two centrosome markers ( Figure 1B ), and importantly, these were not considered as centrosomes. To further characterize and confirm the centrosomal configurations described above, we used 3D structural illumination microscopy (3D-SIM) of ovarian tissues immunostained with the centriolar markerCep135 and PCNT, allowing higher resolution for both centrioles and PCM ( Figure   1D ). To our knowledge this represents the first centrosome super resolution analysis performed in human tissues and tumors. We found that in healthy tissues, each centrosome contained two centrioles and that PCNT surrounded one of the two centrioles, presumably the mother centriole ( Figure 1D ), as expected 33 .
Analysis of tumor tissues revealed the presence of highly heterogeneous conditions with several centrosome abnormalities. Extra centrosomes were easily identified by the presence of multiple CDK5RAP2-PCNT positive co-localizing structures associated with one nucleus ( Figure 1C) . In certain cells, ECs were isolated and spread away from each other ( Figure 1C -top panel) and these were named isolated centrosomes. In other cells, extra centrosomes were clustered together-clustered centrosomes ( Figure 1C , middle panel). Interestingly, we also observed a configuration that to our knowledge has never been described before,
where ECs were tightly associated in a single structure appearing very tightly clustered and hence named super-clusters ( Figure 1C lower panel) . SIM analysis of these tumors, with the markers described above confirmed the aberrant extra centrosome morphologies ( Figure 1E ).
We next quantified the frequency of these defects in a cohort of 19 healthy tissues and 100 tumor tissues. We imaged ten random different fields, corresponding to different regions of the tumor. Importantly, we only imaged and analyzed regions corresponding exclusively to the tumor tissue, excluding regions of stromal tissue that normally surround the tumor. Interestingly, while the majority of tumors (60%)
presented at least one of the defects described above in terms of centrosome number, whereas the remaining 40% of tumors did not show any of these defects ( Figure 1F ). This type of centrosome numerical aberration was never observed in healthy tissues. Still considering only the different type of ECs configurations found in tumors, we observed that 18% of the tumors (n=18, from 100) presented the three categories: isolated, clustered and super-clustered ( Figure 1G ).
All together, the methodology employed to analyse 100 ovarian tumors and comparison with ovarian healthy tissues revealed the presence of centrosome number abnormalities in a large fraction of EOCs.
Extra centrosomes are present in the large majority of EOCs, but high levels of centrosome amplification are infrequent
We next focused our analysis in the quantification of centrosome number abnormalities in tumors. Tumor tissues appeared very disorganized and it was difficult to ascertain the number of centrosomes per cell as in many cases, centrosomes were not closely associated with the nucleus. To unambiguously quantify centrosome number and to be able to compare all tumors and healthy tissues, we visually counted the number of nuclei and the number of centrosomes in each of the ten randomly chosen fields, and determined the Centrosome Nuclei Index (CNI) by dividing the number of centrosomes by the number of nuclei. It is important to mention that we tried to automatize centrosome and nuclear segmentation followed by quantification. This approach was however far from reproducing the manual counting, with a strong bias towards considering unrelated structures as centrosomes. The data we present therefore results from manual counting.
Overall our analysis comprised a total of 653627 nuclei, 874766 centrosomes from 1174 fields, with an average of 5248 nuclei counted per tumor. In healthy tissues, the average CNI was 1.02±0.02 and it was relatively stable, varying from 0.81 to 1.16 ( Figure 2A ). In tumors, however, the CNI was much more variable. On average, 1.43±0.038, with the minimum 0.61 and maximum at 2.55. Interestingly, 89% (n=89 out of 100) of the tumors presented a CNI superior to the average CNI found in healthy tissues ( Figure 2A , yellow dashed line and Supplementary Figure   1A ). However, only 9% (n=9 out of 100) of tumor tissues exhibited centrosome amplification ( Figure 2A , green dashed line), when defined by the presence of more than two centrosomes in a cell 7, 34, 35 . We also investigated the frequency of extra centrosomes clusters and super-clusters per nuclei, and found that they were extremely uncommon (0.71%±0.09 for clusters and 0.72%±0.08 for super-clusters)
(Supplementary Figure 1B) , confirming the low frequencies of extra centrosomes in these tumors.
We next dichotomized our population in two groups using Classification And Regression Trees (CART) methods 36 , restricting the analysis to the high-grade serous ovarian cancers (HGSOCs) within our cohort. These represented the majority of the tumors-88%, which is also the case worldwide for EOCs 24 . This resulted in the categorization of the cohort into low CNI (≤ 1.45) and high CNI (> 1.45), with 55 tumors falling into the low CNI category, while 33 were placed in the high CNI category ( Figure 2A , red line).
We first investigated whether the dichotomization of our tumor cohort in low and high CNI identified any preference for the different extra centrosome categories (isolated, cluster and super-cluster) identified by microscopy. Using multivariated analysis, we recognized a significant trend for isolated centrosomes and clusters (p= We concluded that EOCs are highly heterogeneous in terms of centrosome numbers, and surprisingly only a small population of tumor cells display extra centrosomes.
The CNI does not correlate with proliferation, mitotic indexes, genomic alterations or transcriptomic changes in HGSOCs
We next wanted to study the possible correlation between CNI and different molecular and clinical parameters. We analyzed whether the CNI status correlated with proliferation. We used two indicators, the mitotic index (MI) and, the proliferation marker Ki67 by H&E staining and immunochemistry respectively. Interestingly, we did not find any correlation between CNI and MI or Ki67 (Supplementary Figure 2A- B), suggesting that both CNI low and CNI high tumors show similar proliferative and mitotic indexes.
Genomic alterations are frequently found in HGSOCs 26, 32 . Centrosome defects can lead to mitotic errors, chromosome instability and aneuploidy 37, 38 . In order to identify a possible link between centrosome number and genomic alterations, we used high resolution Cytoscan arrays and GAP tools 39 . With these tools, we analyzed information related with chromosome content (ploidy) and the presence of small and/or large DNA structural rearrangements. Importantly, we did not find any correlation between CNI status and ploidy, chromosome number and DNA structural rearrangements (Supplementary Figure 2C -F). We concluded that small or large chromosome breaks were not associated with low and high CNI tumors.
Different pan-cancer studies 40, 41 have shown that whole genome duplications (WGD) precedes many different types of genomic alterations. WGDs might represent a mechanism to generate aneuploidy, leading to chromosome number reduction, as shown in a mouse ovarian cancer model 42 . WGD-positive (near tetraploid) tumors contain a ploidy of 3.31 on average, while ploidy is closer to ~1.99 (near diploid) for WGD-negative tumors 41 . Centrosome amplification and WGD are hallmarks that have been associated, as both can be produced via the same mechanisms such as cytokinesis failure 40 . We therefore examined if CNI correlated with ploidy in our tumor cohort. We found that this was not the case (Supplementary Figure 2G) , even if we noticed that tumors with low CNI contained twice more near tetraploid (67%, n=26 out of 39 total tumors), than near diploid karyotypes (33%, n=13 out of 39 total tumors). In tumors with high CNI however, the distribution was similar for near tetraploid (46%, n=13 out 28 total tumors) and for near diploid (54%, n=15 out of 28 total tumors), (Supplementary Figure 2G ). This suggests that cytokinesis failure is not the only mechanistic explanation for extra centrosome accumulation, or that
there are yet unidentified centrosome reduction mechanisms at play. Moreover, even
if not statistically significant, low CNI seems to be associated with WGD and hence with worse clinical prognosis 40 .
We also analyzed the transcriptome of our cohort using Affymetrix U133Plus2.0 microarray technology with the aim of identifying altered transcriptomic signatures. Interestingly, we did not find any major differences in gene expression between low and high CNI tumors, even when considering the extreme low or high CNI HGSOCs (not shown). We next compared with published HGSOCs transcriptome signatures, which have described fibrosis and stress profiles due to the expression of mesenchymal and oxidative stress genes, respectively 25 . We found that while high CNI tumors display equivalent distributions between fibrosis and stress tumors, a tendency for fibrosis (63%, n=29 out of 46) was found in low CNI tumors (Supplementary Figure 2H) . We conclude that no major transcriptomic alterations correlate with CNI. Interestingly however, low CNI tumors seem to display characteristics typical of fibrosis type, which are of poor prognosis.
High CNI correlates with better overall survival and response to chemotherapy in HGSOCs
The results described above suggested that low CNI is associated with worse prognosis. To independently test this possibility, we plotted patient survival curves according to the CNI status. We found that low CNI was associated with worse overall survival ( Figure 3A , Log-rank test: p=0.018, HR=1.931, 95% CI=[1.14-3.28])
and furthermore with an increased risk of relapse, ( Figure 3B , Log-rank test:
p=0.018, HR=1.706, 95% CI=[1.06-2.75]). In contrast, high CNI was associated with better overall survival. To avoid any bias due to tumour stage in the prognostic value of CNI, we thus investigated whether the CNI status reflected FIGO staging 43 ).
Importantly, we found that both low and high CNI tumors could be identified at all stages (I to IV) (Supplementary Figure 3A) . Interestingly, the majority of the cases in our cohort correspond to stage III (59.0%, Supplementary Table 1 ) and these comprise once more low and high CNI tumours. We concluded that the association between high CNI and patient survival does not depend on tumor stage.
Relapse is a challenging situation in HGSOCs. Patients are categorized according to their response to chemotherapy and women who relapse within 6 months after the completion of the first line of chemotherapy are defined as platinum resistants 44 . We tested if the CNI parameter can be used as an indicator of relapse, defining early and late as before or after 6 months. We used predictiveness curves 45 to evaluate the performance (robustness) of the CNI as a classifier and the optimum threshold allowing to stratify patients according to relapse. We performed this analysis taking into consideration the presence of extra centrosomes, since 63%
(n=56 out of 88) of our HGSOC cohort harbour these defects. Using boostrap resampling process, our predictiveness curves showed that the optimum CNI value Interestingly however, patients harbouring HR deficiency (HRD) are more sensitive to platinum, one of the two main chemotherapy for EOCs. We investigated whether there was an association between HRD and CNI status using the Large-scale transition (LST) genomic signature 47, 48 . This signature is based on the presence of large-scale chromosome breakpoints of at least 10Mb, which is an indicator of HRD.
While low CNI status contained similar distributions of HRD and HR proficient (HRP) tumors (45% and 55% respectively), high CNI was mainly associated with HRD tumors (74% HRD and 26% HRP, respectively p= 0.024) ( Figure 3C ). Importantly, analysis of HRD patient overall survival did not show any significant association with the CNI status ( Figure 3D, p=0 
Investigating the effect of chemotherapy according to CNI
The treatment of EOCs relies on a combination of platinum and taxane derivative agents, which target DNA integrity and the microtubule cytoskeleton respectively 44 .
We wondered whether there was an association between the CNI and the response to chemotherapy, which could explain the different response to treatment in patients with low and high CNI. We first tested the effect of a combination of carboplatin and paclitaxel in cells lines, where centrosome number can be easily manipulated. In order to increase centrosome number, we generated iOVCAR8-Plk4 and iSKOV3-Plk4 stable cells lines, where the over-expression of Plk4 (Plk4OE), the master centriole duplication kinase can be induced with Doxycycline (Dox) (hence referred to as Plk4OE+), a strategy previously used to amplify centrosomes ( Figure 4A ) 49 .
Centrinone, a Plk4 inhibitor 50 was used to decrease centrosome numbers ( Figure   4A ), and it will be referred to as centrinone cells. 
Low CNI ovarian cancer cells cause more efficient mesothelial cell clearance
It has been shown that centrosome amplification induces invasive oncogenic-like features in a 3-D culture mammary cell (MCF10A) model, both in cell or non-cell autonomous manner 13, 14 . Importantly, the levels of an activated form of RAC1, a small GTPase with described oncogenic signalling properties 13 , were increased. We thus tested whether centrosome number alterations lead to RAC1 activation in ovarian cancer cell lines. We did not observe any significant difference in activated RAC1 levels in response to Dox or centrinone treatment (Supplementary Figure 5A-D) . Thus, the differences observed between these two experimental condition seem to be justified by differential tissue specific responses to centrosome numerical alterations, as already described in flies and mice 8, 9, 11, 12, 35, 54 .
EOCs undergo a particular mode of motility, where tumor cell invade the peritoneal cavity through a process called tumor dissemination 55 . Indeed tumor cells detach from the primary tumor site, adhere and go through mesothelial cells that enclose peritoneal organs 56 . Since centrosome number alterations have been shown to impact cell migration and invasion 3,13,57 , we hypothesized that differences in centrosome number might influence the capacity of ovarian cancer cells to invade the mesothelial barrier. We performed in vitro mesothelial clearance assays using ovarian cancer spheroids derived from iOVCAR8-Plk4 and iSKOV3-Plk4 described above ( Figure 5A ). Cells were treated for 4 days with Dox or centrinone to induce centrosome number alterations. In the last two days, they were plated on polyHEMA, to induce spheroid assembly. Importantly, we verified that this treatment did not 
Discussion
Whereas centrosome number alterations, namely centrosome amplification, has been shown to be sufficient to initiate tumorigenesis in animals [8] [9] [10] [11] [12] , the frequency of centrosome amplification in human tumors has remained under investigated. Here, we analyzed a large cohort of human ovarian tumors and we found that centrosome amplification is less frequent than what has been found in most human cancer cell lines, including ovarian cancer cell lines ( 59 and this study-where CNI determination has been used for HGSOCs). Importantly, our study shows a higher heterogeneity in the number of centrosomes in ovarian tumors, with certain nuclei presenting over 15 centrosomes, while others even lack centrosomes. Tumor heterogeneity has been reported for many different tumor features and this work shows that heterogeneity of centrosome numbers is a hallmark of ovarian tumors.
Centrosome amplification has been correlated with aneuploidy and chromosome instability, however, a correlation between centrosome number increase and aneuploidy was not found in this cohort. These results suggest that even if centrosome amplification might contribute to chromosome number alterations, this is not the only mean by which ovarian tumors become aneuploid.
Furthermore, our work also suggests that centrosome numbers do not influence the global rate of proliferation as revealed by Ki67 and mitotic index analyses. In vertebrates, p53 inhibits the proliferation of cells lacking centrosomes 50 and in cells with extra centrosomes 49, 60 . However since p53, is found mutated in the large majority of ovarian tumors 26 , centrosome number alterations most likely do not influence cell cycle progression or trigger cell cycle arrest.
Although still limited to a few tumor types, observations in certain tumors or in cancer cell lines derived from advanced tumors grades have suggested that centrosome amplification is correlated with advanced tumor stages and worse tumor prognosis 61 . Surprisingly, however, in the EOC cohort analyzed in this study, which comprises in its large majority high-grade tumors, centrosome amplification was not frequent. And more surprisingly, increased centrosome numbers in high CNI tumors correlated with better prognosis. Patient overall survival was increased in tumors with high CNI, and time to relapse, was also found to be increased in the same group of patients. In contrast, patients with low CNI presented decreased survival and showed short-term relapse ( Figure 6 ).
It is possible that many different factors contribute to the positive association between high CNI and patient outcome in EOCs identified in this study. Our work has identified two important contributions. The first one is related with chemotherapy.
We found that both in PDXs and in one ovarian cell line (OVCAR8), centrosome amplification delays tumor growth and decreases cell viability. This chemosensitivity is not due to HRD status since we used two PDXs models derived from HRP tumors, the ones that present worse prognosis. The fact that centrosome amplification did not influence chemotherapy in SKOV3 cell lines, suggests the contribution of differences in the genetic background of each cell line. Additional experiments should address the mechanisms underlying chemotherapy sensitivity in ovarian cancer cells with extra centrosomes. Since taxol targets and stabilizes the microtubule cytoskeleton, it is tempting to speculate that the combination of extra centrosomes and taxol might inhibit centrosome clustering, leading to multipolar cell division and so decreasing tumor cell viability 62 .
The findings that ovarian cancer cell lines containing extra centrosomes showed decreased mesothelial cell clearance capacity was surprising in light of the results found in breast cells 13, 14 , suggesting once more that tissue specific properties influence the consequences of altered centrosome numbers. Ovarian tumors do not show typical invasion features seen in other tumor types 63 . Indeed peritoneal metastases via transcoelomic dissemination appear to be a characteristic of HGSOCs 55, 64 , where tumor cells detach from the primary tumor, using the ascitic fluid as a carrier to reach mesothelial cells that line the peritoneal cavity 56, 65 .
Importantly however, we show that decreased centrosome number confers an advantage to ovarian cancer cell dissemination ( Figure 6 ). These results, together Together, these conditions might facilitate tumor progression and relapse.
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